The schedule of the meeting includes 20 plenary conferences (30 min) organised in 4 different sessions. The attendants are encouraged to present their work in poster communications. The scientific committee that organises this meeting will select a reduced number of these communications to be presented as short talks (10 min). The summaries of the conferences, short talks and poster communications will be published in the abstract book of the congress.




May 26th


9.15-9.30  Welcome organizers

9.30-10.15  The EMBO Lecture:

  Robert A. Weinberg, Whitehead, Institute for Biomedical   Research, Cambridge MA, USA.

  EMT, Cancer Stem Cells, and HIgh-Grade Malignancy”



Session I: Epigenetic control of metastasis



10.15-10.50  Manel Esteller, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

   “Epigenetic contributions to Metastasis and angiogenesis


10.50-11.25  Thomas Brabletz, University of Freiburg, Freiburg, Germany.

   Tumor invasion and metastasis: MicroRNAs, EMT and Cancer Stem Cells


11.25-11.50  COFFEE BREAK


11.50-12.25  Danny R. Welch, University of Alabama, Birmingham AL, USA.

   “Metastasis Suppressors - Genetics, Epigenetics and the Tumor Microenvironment”


12.25-13.00  Frank J. Rauscher, III, The Wistar Institute Cancer Center, Philadelphia, USA.

   Snail Mediated Transcriptional Repression and EMT Requires Zinc-Finger and SNAG domain directed Phosphorylation: Identification of the Kinases and Evaluation as Therapeutic Targets.”


13.00-13.10  Short talk: Roger Gomis, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.

   Mechanisms of CRC metastasis to the liver and lung”


13.10-13.20  Short talk: Rakesh Kumar, George Washington University, Washington, DC, USA

   Transcription Regulation of Tumor Suppressor and EMT Components by MTA1 Master Coregulator”





Session II: Tumor cell invasion


15.00-15.35  Gerhard Christofori, University of Basel, Basel, Switzerland.

   Transcriptional control of EMT and cancer metastasis”


15.35-16.10  Johanna Joyce, Memorial Sloan Kettering Cancer Center, New York, USA.

   The tumor microenvironment in cancer progression and   response to therapy”


16.10-16.45  Raghu Kalluri, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA.

   “Tumor microenvironment controls the rate of metastasis”


16.45-17.05  COFFEE BREAK


17.05-17.40  Klaus Pantel, Universitätsklinikum Hamburg Eppendorf Germany.

   “Circulating tumor cells in cancer patients: Detection,   biology and clinical implications”


17.40-18.15  Cristoph Klein, University of Regensburg, Regensburg, Germany.

   The dynamics of systemic cancer spread



Session III: Mechanisms of angiogenesis.


18.15-18.50  Peter Carmeliet, Vesalius Research Center VIB - KU Leuven, Belgium.

   Third generation anti-angiogenic strategies: novel players, novel principles


18.50-19.35  POSTER SESSION II



May 27th

Session III: Mechanisms of angiogenesis (2nd part).


9.30-10.05  Ralf Adams, Max-Planck Institute for Molecular Biomedicine, Münster, Germany.

   Regulation of angiogenesis by Notch and Eph/ephrin signaling


10.05-10.40  Holger Gerhardt, London Research Institute, London, UK.

   “Cell competition and cooperation in the angiogenic sprout”


10.40-11.15  Elisabetta Dejana,University of Milan, Milan, Italy.

   Transcriptional mechanism of endothelial cell differentiation   and angiogenesis”


11.15-11.25  Michael Potente,Institute for Cardiovascular Regeneration, Frankfurt, Germany.

   Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase”


11.25-11.35  Gonzalo Fernandez-Miranda,Institute for Research in Biomedicine, Barcelona, Spain.

   CPEB-4 is a new regulator of angiogenesis in mammals”


11.35-12.00  COFFEE BREAK



Session IV: Tumoral angiogenesis



12.00-12.35  Kari Alitalo, University of Helsinki, Helsinki, Finland.

   “Mechanisms of lymphangiogenesis and lymphatic metastasis”


12.35-12.50  Mariona Graupera, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

   “Insights in PI3K signalling and angiogenesis”


12.50-13.05  Francesc Viņals, Universitat de Barcelona, Institut Catalā d’Oncologia (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

   “TGF-beta signalling during tumor angiogenesis”


13.05-13.20  Oriol Casanovas, Institut Català d'Oncologia (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

“Tumor malignization after antiangiogenic therapies”





15.00-15.35  Robert Kerbel, Sunnybrook Research Institute (SRI), Toronto Ontario, Canada.

   Recent issues emerging from the use of antiangiogenic drugs in the clinic”


15.35-16.10  Harold L. Moses, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

   TGF-beta regulation of chemokine expression and metastasis”


16.10-16.45  Christopher J. Marshall, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK.

   Molecular analysis of signaling pathways involved in tumor cell invasion”


ICC on Metastasis and Angiogenesis 2011 / Cancer Epigenetics and Biology Program